Mutations in the gene encoding the catalytic subunit of the cone photoreceptor phosphodiesterase (PDE6C) have been recently reported in patients with autosomal recessive inherited achromatopsia (ACHM) and early-onset cone photoreceptor dysfunction. Here we present the results of a comprehensive study on PDE6C mutations including the mutation spectrum, its prevalence in a large cohort of ACHM/cone dysfunction patients, the clinical phenotype and the functional characterization of mutant PDE6C proteins. Twelve affected patients from seven independent families segregating PDE6C mutations were identified in our total patient cohort of 492 independent families. Eleven different PDE6C mutations were found including two nonsense mutations, three mutations affecting transcript splicing as shown by minigene assays, one 1 bp-insertion and five missense mutations. We also performed a detailed functional characterization of six missense mutations applying the baculovirus system to express recombinant mutant and wildtype chimeric PDE6C/PDE5 proteins in Sf9 insect cells. Purified proteins were analyzed using Western blotting, phosphodiesterase (PDE) activity measurements as well as inhibition assays by zaprinast and Pg. Four of the six PDE6C missense mutations led to baseline PDE activities and most likely represent functional null alleles. For two mutations, p.E790K and p.Y323N, we observed reduction in PDE activity of approximately 60% and 80%, respectively. We also observed differences for Pg inhibition. The p.E790K mutant, with an IC 50 value of 2.7 nM is 20.7-fold more sensitive for Pg inhibition, whereas the p.Y323N mutant with an IC 50 of 158 nM is 3-fold less sensitive when compared with the wildtype control.
INTRODUCTION
Light detection in the human retina mediated by rod and cone photoreceptors is a complex signal transduction process.
Hereby, the photoreceptor phosphodiesterases (PDE6) play a key role by rapidly decreasing intracellular levels of the second messenger cGMP in the outer segment. Upon light stimulation, * To whom correspondence should be addressed. Tel: +49 7071 29 80702; Fax: +49 7071 29 5725; Email: susanne.kohl@uni-tuebingen.de # The Author 2010. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com the photopigment is excited and in this state activates the G-protein transducin through GDP/GTP exchange and release of the Ga-subunit (Ta). The latter binds and displaces the inhibitory g-subunit (Pg) of the PDE6 (1). This step activates the catalytic PDE6 dimer that rapidly hydrolyzes intracellular cGMP molecules, resulting in the closure of cGMP-gated channels and hyperpolarization of the photoreceptor plasma membrane. cGMP levels are quickly recovered by synthesis through guanylyl cyclases to re-establish the dark-adapted state (1) . Rod and cone photoreceptors employ the same biochemical mechanism, yet the molecular components are unique and specific for either rods or cones. For instance, in rods, a rod-specific Pg blocks the activity of the heterodimeric PDE6ab catalytic core. Cone PDE in contrast is composed of a cone-specific PDEa ′ homodimer, complexed with two cone-specific Pg subunits. Each PDE6 subunit in the catalytic dimer possesses two regulatory GAF domains located at the N-terminal part of the protein and one conserved Cterminal PDE catalytic domain (2, 3) . Functional investigation of PDE6 has been hampered by the failure of recombinant protein expression in bacteria and mammalian cell lines. Therefore, chimeric fusion proteins between PDE6C and the ubiquitously expressed PDE5 have been developed that overcomes this problem (4) (5) (6) . PDE5 and PDE6C are quite similar in terms of domain organization. Both have two N-terminal GAF domains and one catalytic domain located in the C-terminal part of the molecules. In addition, PDE5 and PDE6 share a relatively high homology of the catalytic domains, specificity to cGMP and sensitivity to common catalytic-site inhibitors, such as sildenafil, zaprinast and IBMX (4) .
Loss or dysfunction of any component of the phototransduction cascade results in photoreceptor degeneration and visual function loss in human. Achromatopsia (ACHM) (MIM * 600827) is a congenital or early-onset retinal disorder with cone photoreceptor function loss. Inherited as an autosomal recessive trait, ACHM is characterized by reduced visual acuity, a pendular nystagmus, photophobia, small central scotoma, eccentric fixation and reduced or complete loss of color discrimination. In photopic electroretinographic recordings (ERG), the cone response is absent or markedly diminished, whereas the scotopic rod response is essentially normal. In rare cases, an incomplete form of ACHM can be observed with similar but less severe symptoms. While mutations in CNGA3 (MIM * 600053), CNGB3 (MIM * 605080) and GNAT2 (MIM +139340) are well-documented causes of ACHM (7 -13), very recently mutations in PDE6C have been identified in patients with this disease (14, 15) .
Here we report the results of our comprehensive study on PDE6C mutations including new mutations and a complete mutation spectrum, the prevalence of PDE6C mutations in our cohort of 492 independent ACHM patients/families, the clinical phenotype and detailed functional characterization of six PDE6C missense mutations introduced into chimeric PDE6C/PDE5 enzyme.
RESULTS

Identification of PDE6C mutations
Microsatellite marker analysis for the known ACHM loci was performed in 16 families with at least two affected siblings or evidence of parental consanguinity. Among those, five families (CHRO 9, CHRO 102, CHRO 566, CHRO 572 and CHRO 573) were found to show concordant segregation for the PDE6C locus. Screening of the PDE6C gene by sequencing all coding exons in the index patients revealed the presence of compound heterozygous or homozygous mutations in four of these families. In addition to the previously reported mutations in family CHRO 9 [compound heterozygous for c.481-12T.A and c.1483-2A.G, (15) (Fig. 1A) . All missense mutations affect amino acid residues highly conserved among different species and PDE6 isoforms (Supplementary Material, Figure S1 ).
We then extended our mutation screening to include another 77 independent index patients who did not carry mutations in CNGA3 and CNGB3. In addition to CHRO 287, which was found to be compound heterozygous for two nonsense mutations [c.826C.T/p.R276X and c.2457T.A/p.Y819X, (15)], we found two further patients with mutations in PDE6C: CHRO 319 was compound heterozygous for c.85C.T/p.R29W and c.2144+1G.A, and CHRO 403 homozygous for the missense mutation c.1172C.T/p.P391L ( Fig. 1A and Table 1 ). All mutations showed consistent independent segregation in the respective families.
Minigene assays of putative splicing mutation
All three putative splicing mutations and the c.2368G.A mutation, which represents a substitution of the first nucleotide of exon 21 were analyzed by heterologous splicing assays of minigene constructs in COS7 cells. In addition to the previously reported defects in transcript splicing induced by the c.481-12T.A, the c.1483-2A.G and the c.2368G.A mutations (15), we also observed a splice defect with minigene constructs carrying the c.2144+1G.A mutation. In this case, a cryptic splice site four nucleotides downstream of the genuine 5
′ splice donor site is activated, which results in a frame-shift and the introduction of a premature termination codon (p.M715IfsX2) (Fig. 1B) .
Functional effects of PDE6C missense mutations PDE activity. To investigate the functional consequences of PDE6C missense mutations, we generated a 'humanized' chimeric PDE6C/PDE5 construct for recombinant protein expression in Sf9 insect cells. In addition to the five missense mutations identified in our study, we also included the p.Y323N mutation, reported by Thiadens and co-workers (14) (Fig. 2) . Purified wildtype and mutant chimeric proteins were analyzed for catalytic activity (cGMP hydrolysis) and inhibition by zaprinast and Pg. Four of the mutant proteins (p.R29W, p.R104W, p.P391L and p.H602L) showed only minute catalytic activity that ranged between 4.5% and 8.6% of the normalized chimeric wildtype protein activity. In contrast, we observed considerable residual enzymatic activity for the p.E790K and the p.Y323N mutants. The p.E790K amino acid substitution is located within the catalytic Inhibition of the mutants by Pg. Dose-response relationships for inhibition of cGMP hydrolytic activity by Pg were measured for the chimeric wildtype and the two mutants p.E790K and p.Y323N that showed residual enzymatic activity ( Fig. 3 and Table 2 ). Pg inhibited the chimeric wildtype with an IC 50 value of 56 nM (Fig. 4B) . The IC 50 value of 158 nM for the p.Y323N was approximately 3-fold higher when compared with wildtype, whereas for the p.E790K mutant an IC 50 value of 2.7 nM was obtained. The 20.7-fold shift of the doseresponse curve towards lower Pg concentrations for p.E790K proved to be statistically significant (P ¼ 0.004). The p.E790K substitution remarkably increases the ability of Pg to inhibit the enzyme activity.
Patients' phenotypes. Clinical data were available for all 12 patients with mutations in PDE6C ( Table 3 ). All patients had a clinical diagnosis of ACHM, and a family history compatible with an autosomal recessive trait. Ophthalmoscopic fundus appearance was unremarkable in most subjects, but some patients showed atrophy of the retinal pigment epithelium (RPE) or granular pigmentation in the macula. Two examples for fundus photography and optical coherence tomography (OCT) are shown for a 33-year-old woman (CHRO 319/II:1- Fig. 5A -D) and a 14-year-old boy (CHRO 287/II:1- Fig. 5E -G). Fundus examination was unremarkable in both patients (Fig. 5 ), except for a thin, pale line outlining a circular area of 250 mm diameter around the foveola in the right eye of patient CHRO319/II:1 (Fig. 5A ) and a central cystic macular lesion in both eyes of patient CHRO 287/II:1 ( Fig. 5E and F) . On transfoveal scans, an optically empty cavity was seen in both patients (250 mm diameter for patient CHRO 319/II:1; 720 mm diameter for patient CHRO 287/II:1) above the RPE, corresponding to discontinuity of the photoreceptor layer in the central circular area of the fovea, extending to the internal limiting membrane ( Fig. 5D and G).
Mutation spectrum and prevalence of PDE6C mutations in ACHM patients. From this study and the previous report by Thiadens and co-workers (14), 16 different pathogenic mutations in PDE6C are known to date (Fig. 2 ). This includes nine protein truncation mutations (three nonsense mutations, one frame-shift mutation and five splice site mutation producing aberrant transcripts with altered reading frame), but also seven missense mutations. Two mutations c.85C.T/p.R29W and c.310C.T/p.R104W were found in exon 1, and c.310C.T/p.R104W localizes in the GAFa domain. The c.967T.A/p.Y323N mutation in exon 6 and the c.1172C.T/p.P391L mutation in exon 9 are situated in the second regulatory GAFb domain, while the c.1363A.G/ p.M455V mutation in exon 10 is closely behind that. Two mutations c.1805A.T/p.H602L in exon 14 and c.2368G.A/p.E790K in exon 21 affect the catalytic PDEaseI domain (Fig. 2) . Except for the c.85C.T/p.R29W mutation, which has been found in this study as well as in the study of Thiadens and co-workers (14) , all other mutations were only detected in single families.
Currently our cohort comprises 492 independent patients and families with a clinical diagnosis of autosomal recessive ACHM. Approximately 77% of these patients carry mutations in either CNGA3 (n ¼ 141 patients; 28.7%) or CNGB3 (n ¼ 237 patients; 48.2%), the by far most prevalent gene mutated in ACHM (10,16, unpublished data) . Mutations in GNAT2 and PDE6C are much less prevalent in our cohort (GNAT2-11 families, ((12), unpublished results) and PDE6C-seven families, this study) with a prevalence of 2.2% and 1.4%, respectively.
DISCUSSION
In this paper we compiled all data of our study on PDE6C mutations including new mutations and a complete mutation spectrum, the prevalence of PDE6C mutations in our cohort of 492 independent ACHM patients and families, the clinical phenotype and a detailed functional characterization of PDE6C missense mutations using purified recombinant protein. For the latter, we investigated two novel PDE6C (14, 15) . Up to now, no disease-associated PDE6C mutation had been functionally characterized in detail, leaving uncertainty about the pathogenicity of these missense mutations. The results of our functional analyses now confirm that all six missense mutations are in fact pathogenic. Four mutations (p.R29W, p.R104W, p.P391L and p.H602L) showed highly significant reduction in PDE activity, to almost baseline levels, and are unlikely to mediate any cone function under physiological conditions. For two mutations, p.E790K and p.Y323N, we observed highly significant reduction in PDE activity of approximately 60% and 80%, respectively. The missense mutation p.R29W was observed in one ACHM family in our study and has also been reported by Thiadens and co-workers, in this case in homozygous state (14) . It localizes near the N-terminus of cone PDE6 upstream of the GAFa domain, and affects an amino acid that is conserved among vertebrate PDE6C and PDE6A polypeptides, except for bovine PDE6C (Supplementary Material, Figure S1 ). For this mutant, we observed a complete loss of enzymatic function. In previous studies it has been shown that dimerization of PDE6 is mediated by multiple regions in the N-terminal domain (17) . We therefore reason that the function loss of the p.R29W mutation could be a result of altered dimerization. In family CHRO 319, we found the p.R29W mutation compound heterozygous with an exchange in intron 17, c.2144+1G.A. As shown in heterologous minigene splicing experiments, this mutation affects correct processing of the PDE6C transcript, resulting in a transcript with a frameshift and premature translational termination (Fig. 1B) .
The missense mutation p.R104W was observed in family CHRO 573 homozygously, and represents a novel mutation. This mutation affects an evolutionary highly conserved residue within the first GAFa domain, a region of the protein that non-catalytically binds cGMP and regulates the activity of the enzyme. This mutation resulted in a complete loss of enzymatic function. Arginine 104 is part of a conserved interaction surface of PDE6C GAFa that consists of numerous negatively charged and hydrophobic residues and is likely to interact with the proline-rich polycationic region of Pg (18) . Beyond that, it has been shown that direct binding of the polycationic region of Pg to the GAFa domain stabilizes the noncatalytic cGMP-binding sites (19) . One could speculate that p.R104W affects Pg binding, resulting in a decrease of cGMP affinity and thus leading to a destabilization of nucleotide binding.
The p.P391L substitution was found in family CHRO 403 diagnosed with complete ACHM, whereas the p.Y323N mutation was identified in a family with the incomplete type of this disease, indicating some residual cone function (14) . Both mutations are located in the second regulatory GAFb domain (Fig. 2) . The phenotypic difference between these patients is reflected by clear differences in cGMP hydrolysis activity of the two mutants. Whereas the p.P391L mutation Figure 2 . Overview of the localization of all currently known PDE6C mutations, including seven missense mutations, five splice defects, three nonsense and one frame-shift mutations. Figure 3 . Reduced or loss of catalytic activity of mutant PDE6C/PDE5 chimeras. Equal amounts of purified protein were assayed for cGMP hydrolysis activity. Activities were normalized to the wildtype protein. Untransfected Sf9 insect cells were measured as control for intrinsic PDE activity. For the p.E790K mutant, we obtained activity of approximately 40% and for the p.Y323N mutant, a reduction in PDE activity of around 78%. All the other mutants p.H602L, p.P391L, p.R104W and p.R29W showed only low PDE activity not significantly different from the untransfected control. Triple asterisk ( * * * ) indicates highly significant difference (P , 0.001) in the catalytic activity between wildtype and mutant protein.
virtually abolished cGMP hydrolysis, the p.Y323N mutation retained residual enzymatic activity of 22.3% compared with the wildtype chimeric protein. In addition, the p.Y323N mutant was about 3-fold less sensitive for Pg inhibition than the chimeric wildtype protein. These findings clearly indicate a correlation between the phenotypic outcome and functionality of the mutant chimeric proteins in our in vitro assays. Both mutations in the GAFb domain affect residues that are fully conserved among vertebrate PDE6 proteins. Yet so far, no crystal structure is available for the GAFb domain of PDE6C, which impedes the prediction of the effects of these mutations on the structure and function of this domain. The PDE2 -GAFb crystal structure is the only suitable template to model PDE6C -GAFb, albeit a poor one, because of low homology between these two domains (20) (Fig. 6 ). In this model, Y323 is situated in a loop that has no PDE2 counterpart, thus making it difficult to predict the pathogenic effect. Nevertheless, our data for inhibition with Pg suggests that Y323 contributes to the interaction with Pg. In contrast, P391 is conserved in GAFa and GAFb domains of PDE2, PDE5 and PDE6 and, from the model, appears to be critical for GAFb folding.
Affected subjects in family CHRO 102 carry two PDE6C mutations p.H602L and p.E790K in compound heterozygous state (15) . While the p.H602L mutant showed only baseline activity not significantly different from the untransfected control, we found that the p.E790K mutant still had considerable residual catalytic activity that reached approximately 40% of the wildtype. p.H602L affects the first histidine of the second metal-binding motif (Fig. 2) , a common functional element of PDEs that complexes divalent cations as essential co-factors for PDE catalytic activity (21) . Glutamate 790 is located adjacent to the Pg binding site within the catalytic domain. The residual enzymatic activity of the p.E790K mutant prompted us to investigate further functional parameters of this mutant, notably its affinity for zaprinast, a catalytic-site inhibitor, and for Pg. Inhibition by zaprinast was not altered significantly while Pg inhibition was 20.7-fold more pronounced with an IC 50 value of 2.7 nM compared with 56 nM for the wildtype protein. This apparent alteration in the affinity of the mutant PDE6C to Pg may have a profound effect on the regulation of the catalytic activity under physiological conditions, in particular its activation by Ta †GTP under normal light conditions. In addition to its dual effect at the protein level, the mutation also impairs transcript processing owing to the fact that the nucleotide substitution affects the first nucleotide of exon 21. Applying a heterologous minigene splicing assay, we could show that approximately 40% of the mutant transcripts undergo irregular splicing by skipping exon 21 (15) . Thus, this mutation exhibits a pleiotropic effect on transcript and protein level thatalthough quantitative in nature-is likely to sum up to a strong functional defect.
Up to now, 16 different PDE6C mutations have been identified in patients with autosomal recessive ACHM. Except for the p.R29W mutation, all other mutations were detected only in single families, suggesting a broad spectrum of lowprevalent PDE6C mutations in Caucasians. All patients examined in this study (seven families/12 affected patients) present with nystagmus, photophobia, poor visual acuity (BCVA 0.08-0.40) and total loss of color vision. In standard ERG recordings, cone function was not detectable, whereas rod responses were essentially normal. Ophthalmoscopy in these ACHM patients revealed normal retinal appearance or only minor macular changes, except for patient II:3 and II:4 of family CHRO 9 (15), which presented with an atrophy of the RPE in the macula, which is a typical feature for ACHM patients at 'endstages' (22) . Hyperopia is common in patients with ACHM (10,23), though in our patients with PDE6C mutations refractive errors were quite variable, ranging from 28.00 to +6.00, with the majority of patients (5/7) being myopic (mean spherical equivalent 24.70). Transfoveal OCT scans showed an optical empty cavity in the fovea of approximately 250 mm in diameter with a corresponding defect of the RPE layer (Fig. 5) . Additionally, in parafoveolar OCT scans, an irregular density of the photoreceptor layer was observed. These findings are typical for patients with ACHM (22) .
All genes currently known to cause ACHM: CNGA3, CNGB3, GNAT2 and PDE6C present crucial components of the cone phototransduction cascade. Together, these genes explain the majority ( 80%) of all ACHM cases in our patient collective of 492 independent patients and families. In half of the patients (48.2%), we found mutations in CNGB3, thus representing the main locus for this disease. In 28.7% of the cases CNGA3 mutations were identified, and in a much lower percentage of 2.2% and 1.4%, mutations in GNAT2 and PDE6C, respectively. These figures are derived from the by far largest patient sample investigated (n ¼ 492) so far. These prevalences of the four genes involved in ACHM vary between patient groups of different geographic background: in the work of Thiadens and co-workers mutations in CNGB3 account for 87%, CNGA3 for 5% and PDE6C for less than 1%, while no mutations in GNAT2 were found (13, 14, 24) . But still, in 10-20% of the patients with ACHM, the genetic etiology remains unresolved. Several possibilities may be considered: A general problem in PCR-based screening protocols, as used in this study, is the failure to identify large genomic deletions and rearrangements. Yet, in our long-lasting analysis of these four genes, we have not observed any evidence that this is a common cause in these genes. Another possibility is that the missing mutations are located within introns or in upstream untranslated regulatory sequences, critical for splicing and expression. Such mutations may also account for the disease in the few subjects in which single heterozygous mutations have been found in either CNGA3 or CNGB3 (10, 16) . A third possibility is that at least a fraction of the unsolved cases are owing to mutations in as yet unknown genes, further increasing the genetic heterogeneity in ACHM.
MATERIALS AND METHODS
Patients, clinical examination and DNA isolation
Patients and family members were referred from different ophthalmological or medical genetic institutions and registered at the Molecular Genetics Laboratory, Institute for Ophthalmic Research, Tuebingen, Germany. The clinical diagnoses of ACHM or cone dysfunction were based on disease history, routine ophthalmological examinations, and varying specialized electrophysiological and psychophysical testing including scotopic and photopic ERG, visual acuity and color vision testing. Fundus examination included digital fundus photography and spectral-domain OCT.
The study was performed in accordance with the Declaration of Helsinki and received approval from the Ethical committee of the University of Tubingen. Patients were informed about the objectives of the study and consented to participate. Total genomic DNA was extracted from venous blood samples of patients and family members according to standard procedures.
PCR and sequencing-based PDE6C mutation screening
The 22 coding exons and their flanking intron boundaries of the PDE6C gene were amplified by PCR with genomic DNA as templates and subsequently used for DNA sequencing. PCR amplifications were performed in a total volume of 50 ml using a PCR mix containing 10 mM Tris pH 8. 
Microsatellite analyses
Twelve families with at least two affected siblings were analyzed by marker segregation analysis for 11 different microsatellite markers: D2S113, D2S2311, D2S1897 and D2S388 linked to the CNGA3 locus on chromosome 2q11.2; D8S167, D8S273 and D8S1838 linked to the CNGB3 locus on chromosome 8q21-q22; D1S2651 and D1S495 linked to the GNAT2 locus on chromosome 1p13.1; and D10S185 and D10S571 linked to the PDE6C locus on chromosome 10q24. Genotyping was performed by PCR amplification from genomic DNA, and fragment-sizing on an ABI PRISM 3100 Genetic Analyzer. Genotype calls were made using the Genescan software program. 
Segregation analysis and exclusion in controls
Segregation analysis by DNA sequencing for the presence and independent inheritance of two mutant alleles were performed in all cases for which samples from additional family members were available. 
Heterologous splicing assay
To characterize the c.2144+1G.A mutation, a PDE6C gene segment covering the exons 16 -18, including the entire internal introns and parts of the flanking intronic sequences, respectively, was amplified from genomic DNA applying Pfu Turbo polymerase (Stratagene, Amsterdam, Netherlands) and blunt-end cloned using the pCR-Script PCR Cloning Kit (Stratagene). This insert was excised by restriction enzyme digestion and reinserted into pSPL3_2096, a derivate of pSPL3 (Invitrogen Gmbh, Karlsruhe, Germany) with a stuffer fragment cloned into the original NotI site. Into this wildtype construct, the c.2144+1G.A mutation was introduced by in vitro mutagenesis (Quik Change in vitro Mutagenesis Kit, Stratagene). Wildtype and mutant constructs were partially sequenced, including the site of the mutation, the vector/ insert and all exon/intron boundaries. COS7 cells were cultured in DMEM (PAA Laboratories GmbH, Pasching, Austria) supplemented with 5% (vol/vol) non-essential amino acids and 10% fetal calf serum (PAA). Cells were transfected with either mutant or wildtype pSPL3-PDE6C construct using Lipofectamine (Invitrogen). Total RNA was prepared 36 h post-transfection using TRIZOL reagent (Invitrogen), reverse-transcribed with SD6 and SA2, forward and reverse primers that are located in the 5 ′ -tat and 3 ′ -tat exons of the pSPL3 vector, respectively, and AMV reverse transcriptase (Takara RT -PCR Kit; Takara, Saint-Germain-en-Laye, France). The cDNA was amplified with pSPL3 exon primers, and RT -PCR products were directly sequenced.
Generation of chimeric PDE6C/PDE5 expression construct
We generated a 'humanized' PDE6C/PDE5-chimeric expression construct that comprises amino acid residues 1-445 and 741-790 of human PDE6C and residues 516 -781 and 831 -845 of human PDE5 (Fig. 7) analogous to the bovine expression construct Chi16 described previously (5, 25) . For construction, we employed the following plasmids: pXOP-human-PDE6C, pHis6-Chi8, pFastHTb-Chi16, pET15b-human-PDE5 and pFast-HTb-PDE5 (5,26). The pHis 6 -hPDE6C-GAF construct was obtained by ligation of NcoI/HindIII as well as NcoI/EcoRI fragments of pXOPhuman-PDE6C into pHis6-Chi8. The pFastHTb-Chi16/PDE5 construct was obtained by ligation of XhoI/HindIII fragment of pFastHTb-PDE5 as well as HindIII/SpeI fragment of human retinal RNA into pFastHTb-Chi16. The PDE5 fragment containing amino acids 831 -845 was obtained using selected restriction sites and the pET15b-humanPDE5 as template and ligation into the pFastHTb-vector. After digestion with XhoI, HindIII, SpeI and NcoI, the fragments were ligated into the pFastHTb-Chi16 vector digested with the same enzymes. The mutations p.R29W (c.85C.T), p.R104W (c.310C.T), p.Y323N (c.967T.A), p.P391L (c.1172C.T), p.H602L (c.1805A.T) and p.E790K (c.2368G.A) were introduced by in vitro mutagenesis (Quik Change in vitro Mutagenesis Kit, Stratagene). The sequences of all PDE6C/PDE5 chimeras, wildtype and mutants, were confirmed by DNA sequencing of both strands. All restriction enzymes were purchased from New England Biolabs (NEB, Frankfurt am Main, Germany).
Expression of PDE6C/PDE5 chimeras in the baculovirus/ Sf9 insect cell system Generation of recombinant bacmids, transfection of Sf9 insect cells and viral amplifications were carried out according to the manufacturers' recommendations (Invitrogen). Sf9 insect cells were cultured in Sf-900 II SFM (Invitrogen) supplemented with 10% fetal calf serum (PAA) and 1% penicillin/streptomycin (PAA). For protein expression, Sf9 insect cell cultures (3 × 10 6 cells/ml in a total volume of 400 ml) were infected with recombinant baculoviruses at MOI 3-5, harvested by centrifugation 72 h after infection and washed with 20 mM 
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